|
NZ530258A
(en)
*
|
2001-07-18 |
2006-01-27 |
Bionomics Ltd |
Mutations in SCN1A SCN2A SCN3A SCN8A sodium ion channels and their use in diagnosing epilepsy
|
|
AU2003904154A0
(en)
|
2003-08-07 |
2003-08-21 |
Bionomics Limited |
Mutations in ion channels
|
|
AU2003901425A0
(en)
*
|
2003-03-27 |
2003-04-10 |
Bionomics Limited |
A diagnostic method for epilepsy
|
|
JP5540343B2
(ja)
*
|
2007-11-06 |
2014-07-02 |
国立大学法人 岡山大学 |
小児てんかん患者における急性脳炎または急性脳症の罹患リスク判定データの取得方法およびその利用
|
|
WO2009084472A1
(ja)
*
|
2007-12-28 |
2009-07-09 |
Public University Corporation Yokohama City University |
新生児期~乳児期発症の難治性てんかんの検出方法
|
|
JP5936067B2
(ja)
|
2009-08-20 |
2016-06-15 |
バイオセプター・(オーストラリア)・ピーティーワイ・リミテッド |
抗p2x7受容体抗体およびその断片
|
|
WO2011093393A1
(ja)
*
|
2010-01-29 |
2011-08-04 |
国立大学法人岡山大学 |
Dravet症候群の発症可能性の判定方法およびその利用
|
|
JP2011188837A
(ja)
*
|
2010-03-16 |
2011-09-29 |
Hirosaki Univ |
リーシークエンスdnaチップおよび最適抗てんかん薬決定方法
|
|
KR101914309B1
(ko)
*
|
2010-06-23 |
2018-11-02 |
큐알엔에이, 인크. |
전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
|
|
TWI734935B
(zh)
*
|
2011-06-24 |
2021-08-01 |
美商可娜公司 |
上調電壓門控鈉離子通道第I型α次單元(SCN1A)之表現及/或功能之反義寡核苷酸及其用途
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
SG11201702494UA
(en)
|
2014-09-29 |
2017-04-27 |
Zogenix Internat Ltd |
Control system for control of distribution of medication
|
|
HK1251965A1
(zh)
*
|
2015-10-30 |
2019-05-10 |
Ptc医疗公司 |
用於治疗癫痫的方法
|
|
ES2882500T3
(es)
|
2015-12-14 |
2021-12-02 |
Cold Spring Harbor Laboratory |
Oligómeros antisentido para el tratamiento del síndrome de Dravet
|
|
JP2019507111A
(ja)
|
2015-12-22 |
2019-03-14 |
ゾゲニクス インターナショナル リミテッド |
代謝抵抗性フェンフルラミン類縁体およびその使用法
|
|
EP3800177B1
(en)
|
2015-12-22 |
2025-01-29 |
Zogenix International Limited |
Fenfluramine compositions and methods of preparing the same
|
|
RU2021106383A
(ru)
|
2016-08-24 |
2021-04-05 |
Зодженикс Интернэшнл Лимитед |
Состав для ингибирования образования агонистов 5-ht2b и способы его применения
|
|
WO2018098491A1
(en)
|
2016-11-28 |
2018-05-31 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
US20210188839A1
(en)
*
|
2016-11-28 |
2021-06-24 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
WO2018098499A1
(en)
|
2016-11-28 |
2018-05-31 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
CN106719436A
(zh)
*
|
2016-12-20 |
2017-05-31 |
郑州伊美诺生物技术有限公司 |
一种制备单克隆抗体的小鼠模型建立方法
|
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
WO2018213491A1
(en)
*
|
2017-05-16 |
2018-11-22 |
Praxis Precision Medicines, Inc. |
Methods of treating epilepsy and neurodevelopmental disorders
|
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
|
SI3673080T1
(sl)
|
2017-08-25 |
2024-03-29 |
Stoke Therapeutics, Inc. |
Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
WO2019118779A2
(en)
|
2017-12-13 |
2019-06-20 |
The Research Foundation For The State University Of New York |
Peptides and other agents for treating pain and increasing pain sensitivity
|
|
WO2019216919A1
(en)
|
2018-05-11 |
2019-11-14 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
US12259378B2
(en)
|
2018-05-25 |
2025-03-25 |
Praxis Precision Medicines, Inc. |
Dynamic clamps and methods of use thereof
|
|
EP4465051A3
(en)
*
|
2018-05-29 |
2025-01-22 |
Cognizance Biomarkers, Inc. |
Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures
|
|
IL309843B2
(en)
|
2018-05-30 |
2026-05-01 |
Praxis Prec Medicines Inc |
History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators
|
|
CA3110211A1
(en)
|
2018-08-20 |
2020-02-27 |
Rogcon, Inc. |
Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
|
|
EA202092908A1
(ru)
|
2018-09-28 |
2021-05-14 |
Праксис Пресижн Медсинз, Инк. |
Модуляторы ионных каналов
|
|
EA202191079A1
(ru)
|
2018-11-19 |
2021-09-20 |
Зодженикс Интернэшнл Лимитед |
Способы лечения синдрома ретта с применением фенфлурамина
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
|
US11767325B2
(en)
|
2019-11-26 |
2023-09-26 |
Praxis Precision Medicines, Inc. |
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
|
|
AU2020392128A1
(en)
|
2019-11-27 |
2022-06-09 |
Praxis Precision Medicines, Inc. |
Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
CA3250706A1
(en)
|
2022-04-26 |
2023-11-02 |
Praxis Precision Medicines, Inc. |
TREATMENT OF NEUROLOGICAL DISORDERS
|
|
CN116024222B
(zh)
*
|
2022-11-30 |
2023-12-22 |
湖南家辉生物技术有限公司 |
一种导致婴儿严重肌阵挛性癫痫的nac1基因突变体及其应用
|